Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound

Giuseppe Della Porta, Tommaso A. Dragani

Research output: Contribution to journalArticle

Abstract

Pildralazine, a hydralazinelike antihypertensive vasodilator containing a free hydrazine group, was administered in the drinking water to male and female B6C3F1 and to female BALB/c mice at 100, 200, and 400 ppm dose levels for 80 weeks. The animals were kept under observation until 130-133 weeks of age, when the experiment was terminated. A transplacentalinfantile bioassay was also carried out with pildralazine administered in the drinking water at 200 and 400 ppm dose levels to female C57BL/6J mice for 1 week before mating with C3Hf males and during mating and pregnancy. The progeny received the same doses for 10 weeks after birth and were kept under observation until 80-85 weeks of age, when the experiment was terminated. In both long-term and transplacental-infantile assays, control and treated groups developed the pattern of tumors usually observed in the strains used and no tumor type at any site appeared to be related to treatment.

Original languageEnglish
Pages (from-to)97-101
Number of pages5
JournalJournal of Cancer Research and Clinical Oncology
Volume106
Issue number2
DOIs
Publication statusPublished - Oct 1983

Keywords

  • B6C3F
  • BALB/c
  • Hydralazine
  • Hydrazine
  • Pildralazine
  • Propildazine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound'. Together they form a unique fingerprint.

  • Cite this